medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (4)


Management of liver metastases of gastrointestinal stromal tumors (GIST)

Vassos N, Agaimy A, Hohenberger W, Croner RS

Idioma: Ingles.
Referencias bibliográficas: 55
Paginas: 531-539
Archivo PDF: 173.64 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors; review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78.

  2. Vassos N, Agaimy A, Hoheneberger W, Croner RS. Extraabdominal lymph node metastasis in gastrointestinal stromal tumors. J Gastrointest Surg 2011; 15: 1232-6.

  3. Miettinen M, El-Rifai W, H L Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478-83.

  4. Patel SR, Benjamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000; 9: 67-70.

  5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-21.

  6. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-39.

  7. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Qeubbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776-85.

  8. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540-47.

  9. Reddy SK, Barbas AS, Marroquin CE, Morse MA, Kuo PC, Clary BM. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg 2007; 204: 372-82.

  10. Nunobe S, Sano T, Shimada K, Sakamoto Y, Kosuge T. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol 2005; 35: 338-41.

  11. Shima Y, Horimi T, Ishikawa T, Ichikawa J, Okabayashi T, Nishioka Y, Hamada M, et al. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg 2003; 10: 77-80.

  12. Chua TC, Chu F, Morris DL. Outcomes of Single-Centre Experience of Hepatic Resection and Cryoablation of Sarcoma Liver Metastases. Am J Clin Oncol 2011; 34: 317-20.

  13. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.

  14. Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, March JW, Tsung A, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer 2012; 118: 3571-8.

  15. Jones RL, McCall J, Adam A, O’Donnell D, Ashley S, Al-Muderis O, Thway K, et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 2010; 36: 477-82.

  16. Ishikawa A, Teratani T, Ono S, Ochiai T, Kakinoki N, Kishimoto Y, Kamoshida T, et al. A case of gastrointestinal stromal tumor with liver and bone metastases effectively treated with radiofrequency ablation and imatinib mesylate. Nihon Shokakibyo Gakkai Zasshi 2006; 103: 1274-9.

  17. Kobayashi K, Gupta S, Trent JC, Vauthey JN, Krishnamurthy S, Ensor J, Ahrar K, et al. Hepatic artery chemoembolisation for 110 gastrointestinal stromal tumors. Cancer 2006; 107: 2833-41.

  18. Kamusella PC, Bethke A, Platzek I, Wiggermann P, Wissgott C, Stroszczynski C. Minimally invasive management of metastases from gastrointestinal stromal tumors. Radiologe 2009; 49: 1132-5.

  19. Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol 2009; 32: 574-81.

  20. Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am 2009; 23: 129-37.

  21. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.

  22. Wahl RL, Jacene H, Kasamom Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(Suppl. 1): 122S-50S.

  23. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-64.

  24. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005; 7: 307-11.

  25. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004; 240: 205-13.

  26. Strasberg SM; The International Hepato-Pancreato-Biliary Association Terminology Committee Survey. The Brisbane 2000 Terminology of Liver Anatomy and Resections. HBP (Oxf) 2000; 2: 333-9.

  27. Fletcher CD, Berman J, Corless CL, Gorstein F, Lasota J, Longley BJ, Miettinen M, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.

  28. Ye YJ, Gao ZD, Poston GJ, Wang S. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumor (GIST). Eur J Surg Oncol 2009; 35: 787-92.

  29. Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009; 23: 115-27.

  30. Marudanayagam R, Sandhu B, Perera MT, Bramhall SR, Mayer D, Buckels JA, Mirza DF. Liver resection for metastatic soft tissue sarcoma: An analysis of prognostic factors. Eur J Surg Oncol 2011; 37: 87-92.

  31. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.

  32. Sato T, Ohyama S, Kokudo N, Suegana M, Yamamoto J, Yamaguchi T, Muto T. The repeated hepatectomy for frequent recurrence of hepatic metastasis from gastrointestinal stromal tumor of the stomach. Hepatogastroenterology 2004; 51: 181-3.

  33. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.

  34. Zhu J, Yang Y, Zhou L, Jiang M, Hou M. A long-term followup of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010; 10: 199.

  35. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421-3.

  36. Zhu J, Wang Y, Hou M, Li HY, Zhang J. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. Oncology 2007; 73: 324-7.

  37. Blanke CD, von Mehren M, Joensuu H, Roberts PJ, Eisenberg B, Heinrich M, Druker B, et al. Evaluation of the molecularly targeted therapy STI571 in patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Proc Am Soc Clin Oncol 2001; 20: 2.

  38. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-52.

  39. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003; 186: 665-9.

  40. Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 2010; 40: 936-42.

  41. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007; 14: 526-32.

  42. Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A, Dudek K, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c- Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003; 50: 438-42.

  43. Apostolopoulos DJ, Dimitrakopoulou-Strauss A, Hohenberger P, Roumia S, Strauss LG. Parametric images via dynamic 18F-fluorodeoxyglucose positron emission tomographic data acquisition in predicting midterm outcome of liver metastases secondary to gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging 2011; 38: 1212-23.

  44. Van de Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradeigm for imaging. Oncologist 2008; 13(Suppl. 2): 8-13.

  45. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004; 183: 1619-28.

  46. Vanel D, Albiter M, Shapeero L, Le Cesne A, Bonvalot S, Le Pechoux C, Terrier P, et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. Eur J Radiol 2005; 54: 118-23.

  47. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Levesha MA, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90.

  48. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreecey LS, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.

  49. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-38.

  50. Demetri GD, van Oosterom A, Blackstein M. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol 2005; 23: 308S.

  51. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593-600.

  52. Ishikawa A, Teratani T, Ono S, Ochiai T, Kakinoki N, Kishimoto Y, Kamoshida T, et al. A case of gastrointestinal stromal tumor with liver and bone metastases effectively treated with radiofrequency ablation and imatinib mesylate. Nippon Shokakibyo Gakkai Zasshi 2006; 103: 1274-9.

  53. Jones RL, McCall J, Adam A, O‘Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C, Judson IR. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol 2010; 36: 477-82.

  54. Pawlik TM, Vanthey JN, Abdolla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141: 537-43.

  55. Radkani P, Ghersi MM, Paramo JC, Mesko TW. A multidisciplinary approach for the treatment of GIST liver metastasis. World J Surg Oncol 2008; 6: 46.




2020     |     www.medigraphic.com